INESSS has launched a modernized website that is more user-friendly and provides greater transparency. Some of the highlighted new features includes:
Enhanced search engine that allows broader searches throughout the full website and that offers additional Advance Search filters.
New Social Services, Drugs and Health Services sections which provide new ... Read More
12
Nov2018
01
Oct2018
Did you or your organization submit written comments to the recent national pharmacare consultation? If so, PDCI has volunteered to accumulate & share submissions from all stakeholders on a centrally located webpage available here.
If you would like your voice added to this important policy discussion, please send ... Read More
28
Aug2018
***Participation Requested***
Sharing Responses to the National Pharmacare Public Consultation
Announced in the 2018 federal budget and chaired by former Ontario Health Minister Eric Hoskins, the Advisory Council on the Implementation of National Pharmacare is currently engaging in a national dialogue on how the federal government could implement ... Read More
27
Aug2018
PMPRB published its 2017 annual report this week, recalling an eventful year (complete with proposed amendments to its overarching regulations, poised to fundamentally change its future mandate & operations) and looking forward in 2018 to working constructively with stakeholders to finalize its Guidelines modernization initiative, underway since 2016.
PMPRB 2017 Annual ... Read More
03
Jul2018
Last week, CADTH shared its new Procedure and Submission Guidelines for the CADTH Common Drug Review document which combines the previously separate procedure and submission guidelines into a single document. Manufacturers are encouraged to follow the new guidelines immediately, however new submission requirements will be only be enforced for ... Read More
28
Jun2018
Health Canada, CADTH, and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) have officially launched efforts to align regulatory and health technology assessment (HTA) drug reviews for eligible submissions, effective immediately.
Background
The new process stems from Health Canada and HTAs recognizing the need for greater coordination of the ... Read More
14
Jun2018
On June 13, 2018, after considerable time in development, the pCPA released its Brand Process Guidelines for external feedback. The pCPA is interested in receiving feedback from all sectors with a stake in the negotiation process: brand and generic pharmaceutical companies, patient organizations, and other interested parties.
The guidance documents, which ... Read More
31
May2018
2019 CDEC Meeting Schedule Released
A new schedule format includes submission deadlines and guidance on when manufacturers can expect embargoed and final recommendations.
Updated Advance Notification Form (effective immediately)
New form includes an acknowledgement that information provided in the form may be shared with federal, provincial and territorial ... Read More
11
May2018
PMPRB has released its May 2018 NEWSletter which includes anticipated updates on PMPRB’s timelines for its Guidelines modernization initiative:
June 2018:
PMPRB to release more specific guidance on how the PMPRB foresees operationalizing regulatory changes
PMPRB to form a multi-stakeholder Working Group to gather input on key technical aspects of ... Read More
04
May2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30th, 2018:
46 negotiations are currently underway with 7 new files added since the last update of March 31st, 2018:
Adlyxine (lixisenatide): Used to treat type 2 diabetes mellitus
Ilaris (canakinumab): Used ... Read More